GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » PB Ratio

BioNexus Gene Lab (BioNexus Gene Lab) PB Ratio : 1.06 (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-14), BioNexus Gene Lab's share price is $0.5801. BioNexus Gene Lab's Book Value per Share for the quarter that ended in Dec. 2023 was $0.55. Hence, BioNexus Gene Lab's PB Ratio of today is 1.06.

The historical rank and industry rank for BioNexus Gene Lab's PB Ratio or its related term are showing as below:

BGLC' s PB Ratio Range Over the Past 10 Years
Min: 0.61   Med: 29.04   Max: 301.65
Current: 1.05

During the past 6 years, BioNexus Gene Lab's highest PB Ratio was 301.65. The lowest was 0.61. And the median was 29.04.

BGLC's PB Ratio is ranked better than
71.76% of 1530 companies
in the Chemicals industry
Industry Median: 1.63 vs BGLC: 1.05

During the past 12 months, BioNexus Gene Lab's average Book Value Per Share Growth Rate was 18.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 5.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 31.00% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of BioNexus Gene Lab was 52.00% per year. The lowest was 5.40% per year. And the median was 41.40% per year.

Back to Basics: PB Ratio


BioNexus Gene Lab PB Ratio Historical Data

The historical data trend for BioNexus Gene Lab's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab PB Ratio Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 59.10 50.82 24.78 0.97

BioNexus Gene Lab Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.78 14.30 6.44 1.60 0.97

Competitive Comparison of BioNexus Gene Lab's PB Ratio

For the Specialty Chemicals subindustry, BioNexus Gene Lab's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNexus Gene Lab's PB Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's PB Ratio distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's PB Ratio falls into.



BioNexus Gene Lab PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

BioNexus Gene Lab's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.5801/0.547
=1.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


BioNexus Gene Lab  (NAS:BGLC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


BioNexus Gene Lab PB Ratio Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNexus Gene Lab (BioNexus Gene Lab) Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Executives
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong director, officer: President 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong officer: Chief Financial Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong director, officer: Chief Operating Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh director, officer: Chief Executive Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200